BioSpace News Archive

Protocol W trial data confirm results from PANORAMA trial showing EYLEA significantly reduced vision-threatening complications and improved anatomic measures of diabetic retinopathy Although patients’ overall vision was similar in the EYLEA and sham groups at two years in Protocol W, a new analysis from PANORAMA

- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, metabolic, autoimmune and other major diseases, today announced that the Center for Drug Evaluation (CDE) of China’s Nation

3D Medicines to Lead the Manufacture, Clinical Development and Commercialization of IMC-002 for Oncology indications in Greater China

Phase 2 basket trial will be conducted in patients with relapse/refractory esophageal squamous cell carcinoma, gastric cancer, and cervical cancer

Chinese leading biopharmaceutical company 3SBio unveiled its 2020 full-year results. The Company maintained stable profitability despite the huge challenge amid the COVID-19 pandemic, while ushering in new milestones.

Companies have successfully submitted the EU regulatory application for marketing authorization for difelikefalin

Since the anti-inflammatory effect of the nasally administered Foralumab is through the modulation of the immune system and not by directly targeting Covid-19, this therapeutic approach could be useful for newly identified Covid-19 variants in the UK, South Africa and Brazil.

Delivering on strategy to accelerate commercialisation of the Parsortix system and act as a demonstrator to support product deployment

Vitrolife has published its Annual Report for 2020.

IRRAS’s annual report 2020 has been published on the company’s website.